会计师 穿今所（特殊普通合伙） i Contilied Public Secountants (Shecial General Partnorship) 上会会计师事务所（特殊普通合伙） 关于无锡晶海氨基酸股份有限公司 关于无锡晶海氨基酸股份有限公司 募集资金存放与使用情况的鉴证报告 上会师报字(2025)第 4059 号 中国 上海 2024 年度募集资金存放与使用情况的鉴证报告 上会师报字(2025)第 4059 号 无锡晶海氨基酸股份有限公司全体股东: 我们接受委托,对后附的无锡晶海氨基酸股份有限公司(以下简称"贵公司") 《关于 2024 年度公司募集资金存放与实际使用情况的专项报告》执行了鉴证工作。 一、管理层对募集资金专项报告的责任 按照中国证监会发布的《上市公司监管指引第 2 号一上市公司募集资金管理和 使用的监管要求》和北京证券交易所颁布的《北京证券交易所股票上市规则(试行)》 等有关规定编制《关于 2024 年度公司募集资金存放与实际使用情况的专项报告》是 贵公司董事会的责任。这种责任包括设计、实施和维护与募集资金专项报告编制相 关的内部控制,保证募集资金专项报告的真实、准确和完整,以及不存 ...

| 关联交易类别 | 主要交易内 | 预计 | 2025 2024 | 年与关联方 | 预计金额与上年实际发 生金额差异较大的原因 | | --- | --- | --- | --- | --- | --- | | | 容 | 年发生金额 | | 实际发生金额 | （如有） | | 购买原材料、 | | | | | | | 燃料和动力、 | | | | | | | 接受劳务 | | | | | | | 销售产品、商 | 出售产品、 | 5,000,000 | | 0 | | | 品、提供劳务 | 提供加工 | | | | | | 委托关联方销 | | | | | | | 售产品、商品 | | | | | | | 接受关联方委 | | | | | | | 托代为销售其 | | | | | | | 产品、商品 | | | | | | | 其他 | | | | | | | 合计 | - | 5,000,000 | | 0 | - | （二）关联方基本情况 关联方名称：无锡晶扬生物科技有限公司 法定代表人：董亮 证券代码：836547 证券简称: 无锡晶海 公告编号：2025-032 无锡晶海氨基酸股份有限公司 关于 ...

无锡晶海氨基酸股份有限公司 2024 年度会计师事务所履职情况评估报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 证券代码：836547 证券简称：无锡晶海 公告编号：2025-037 无锡晶海氨基酸股份有限公司（以下简称"公司"）聘请上会会 计师事务所（特殊普通合伙）（以下简称"上会"）作为公司 2024 年 度审计机构。根据财政部、国务院国有资产监督管理委员会、中国证 券监督管理委员会颁布的《国有企业、上市公司选聘会计师事务所管 理办法》，公司对上会在 2024 年度的审计工作的履职情况进行了评 估。具体情况如下： 一、会计师事务所基本情况 1、会计师事务所基本情况 名称：上会会计师事务所（特殊普通合伙） 统一社会信用代码：91310106086242261L 类型：特殊普通合伙企业 主要经营场所：上海市静安区威海路 755 号 25 层 执行事务合伙人：朱清滨、巢序、杨滢、耿磊、张健、张晓荣、江燕 成立日期：2013 年 12 月 27 日 经营范围：审查企业会计报表，出具审计报告；验证企业 ...

为了提高公司资金利用效率，增加投资收益，在不影响公司主 营业务的正常发展，并确保公司经营需求的前提下，公司拟利用闲 置自有资金购买商业银行理财产品等监管机构批准的金融理财产 品，获得额外的资金收益。 （二） 委托理财金额和资金来源 公司现授权使用不超过人民币 2 亿元的自有闲置资金进行投资 理财，即授权期限内任一时点持有的未到期投资产品总额不超过人 民币 2 亿元，在此额度内，资金可滚动使用。 购买理财产品的资金仅限于公司自有闲置资金。 （三） 委托理财方式 1、预计委托理财额度的情形 证券代码：836547 证券简称：无锡晶海 公告编号：2025-035 无锡晶海氨基酸股份有限公司 关于公司使用闲置自有资金投资理财的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担 个别及连带法律责任。 一、 委托理财概述 （一） 委托理财目的 此议案经第四届董事会第八次会议和第四届监事会第七次会 议审议通过。本议案不涉及关联事项，无需回避表决。 该议案尚需提交 2024 年年度股东大会审议通过。 三、 风险分析及风控措施 公司运用自有 ...

证券代码：836547 证券简称：无锡晶海 公告编号：2025-040 无锡晶海氨基酸股份有限公司 关于对公司董事、监事、高级管理人员 2024 年度薪酬予以 确认及 2025 年度薪酬方案的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 无锡晶海氨基酸股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开了第四届董事会第八次会议和第四届监事会第七次会议， 分别审议通过了《关于对公司董事 2024 年度薪酬予以确认及公司董 事 2025 年度薪酬方案的议案》《关于对公司监事 2024 年度薪酬予以 确认及公司监事 2025 年度薪酬方案的议案》《关于对公司高级管理人 员 2024 年度薪酬予以确认及公司高级管理人员 2025 年度薪酬方案 的议案》，相关董事和监事回避表决，并同意提交公司 2024 年年度股 东大会审议。现将相关情况公告如下： 一、公司董事、监事、高级管理人员 2024 年度薪酬情况 结合 2024 年度实际经营情况，对公司董事、监事、高级管理人 员 2024 年度 ...

证券代码：836547 证券简称：无锡晶海 公告编号：2025-039 无锡晶海氨基酸股份有限公司 董事会审计委员会 2024 年度履职情况报告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 2、审阅公司财务报告并发表意见 报告期内，审计委员会审议了公司定期报告相关事项，与公司管 理层进行了有效沟通，认为公司财务报告的编制符合法律法规和中国 证券监督管理委员会、北京证券交易所的相关规定，财务报告的内容 真实、准确、完整地反映了公司的经营成果、财务状况和现金流量情 况，不存在虚假记载、误导性陈述或者重大遗漏。 无锡晶海氨基酸股份有限公司（以下简称"公司"）第四届董事 会审计委员会根据《公司法》《证券法》《上市公司独立董事管理办法》 《北京证券交易所股票上市规则（试行）》和《公司章程》《董事会专 门委员会工作制度》等相关法律法规及公司制度的规定和要求，在 2024 年度认真履职。现将本年度履职情况汇报如下： 一、成员构成 报告期内，独立董事陈坚先生因个人原因离职，经公司 2024 年 第六次临时股东大会审 ...

根据独立董事向董事会提供的关于独立性情况的自查报告，结合 其他相关资料，董事会就独立董事的独立性形成如下结论： （一）独立董事及其配偶、父母、子女、具有主要社会关系的人 员未在公司或公司附属企业任职； （二）独立董事及其配偶、父母、子女未直接或间接持有公司已 发行股份百分之一以上，不是公司前十名股东中的自然人股东； 证券代码：836547 证券简称：无锡晶海 公告编号：2025-029 无锡晶海氨基酸股份有限公司 董事会关于独立董事独立性情况的专项意见 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 根据中国证券监督管理委员会《上市公司独立董事管理办法》等 相关规定，无锡晶海氨基酸股份有限公司（以下简称"公司"）董事 会就公司在任独立董事饶志明、李苒洲的独立性情况进行评估并出具 了专项意见。 董事会 （三）独立董事及其配偶、父母、子女不是直接或间接持有公司 已发行股份百分之五以上的股东，未在公司前五名股东任职； （四）独立董事及其配偶、父母、子女未在公司控股股东、实际 控制人的附属企业任职； （五）公司 ...

Financial Performance - The company's operating revenue for 2024 was CNY 338,978,845.97, a decrease of 12.87% compared to CNY 389,062,366.11 in 2023[27]. - The net profit attributable to shareholders for 2024 was CNY 42,851,041.14, down 19.76% from CNY 53,405,601.20 in 2023[27]. - The gross profit margin for 2024 was 30.47%, a decline from 32.73% in 2023[27]. - The basic earnings per share for 2024 was CNY 0.55, representing a decrease of 42.11% from CNY 0.95 in 2023[27]. - Operating cash flow decreased significantly by 67.98% to ¥41,075,608.66 compared to the previous year[28]. - The weighted average return on net assets attributable to shareholders was 6.73% in 2024, down from 15.47% in 2023[27]. - Total revenue for the reporting period was CNY 338,978,845.97, with a gross profit margin of 30.54%[70]. - The company's main business income decreased by 13.04% to CNY 336,064,043.85 in 2024 from CNY 386,467,178.94 in 2023[67]. - The financial expenses increased by 160.99% due to higher interest income from idle funds and foreign exchange gains[65]. - The credit impairment loss surged by 3167.49% due to a specific overdue receivable, which has since been fully recovered[65]. Assets and Liabilities - Total assets increased by 7.16% to ¥803,935,578.14 compared to the end of 2023[28]. - Total liabilities decreased by 12.08% to ¥143,457,042.34 compared to the end of 2023[28]. - The company's cash and cash equivalents decreased by 82.13% to CNY 55.58 million in 2024, primarily due to investments in structured deposits and a reduction in raised funds[58]. - The company's accounts receivable decreased by 11.02% to CNY 65.01 million, reflecting a reduction in bank acceptance bills with higher credit risk[57]. - The company's fixed assets increased by 71.44% to CNY 69.41 million, indicating significant investment in long-term assets[57]. - The company's inventory decreased by 5.14% to CNY 59.30 million, suggesting improved inventory management[57]. - The company's total liabilities decreased significantly, with short-term borrowings reduced to zero, indicating improved financial stability[56]. Research and Development - The company's R&D investment was 18.16 million yuan, accounting for 5.36% of total revenue[48]. - The company reported a total of 18,162,788.84 CNY in R&D expenses, which represents 5.36% of its operating revenue[93]. - The previous year's R&D expenses were 19,822,672.67 CNY, accounting for 5.09% of operating revenue, indicating a decrease in absolute terms[93]. - The company has committed to R&D expenses of RMB 3 million for the development of 4-hydroxyisoleucine through a collaboration with East China University of Science and Technology[99]. - The top R&D project, focusing on low solubility amino acid purification, received ¥7.52 million in the current period and is in the industrialization verification stage[182]. - The company is developing high-purity L-lysine and low-solubility amino acid purification technologies, aiming to enhance product quality and expand market sales[97]. - The company has established a dedicated research team focused on technology innovation and R&D, ensuring the protection of core technologies through confidentiality agreements[174]. Market and Industry Position - The company operates in the pharmaceutical manufacturing industry, specifically in the production of amino acid products[20]. - The global amino acid market size reached $26.19 billion in 2021 and is expected to grow to $49.42 billion by 2030[50]. - The global amino acid production scale is expected to reach 13.8 million tons by 2027, up from over 10 million tons in 2021[50]. - The company's amino acid products are primarily used in the pharmaceutical industry, with the pharmaceutical manufacturing industry's revenue in 2024 expected to be CNY 2,529.85 billion, remaining flat compared to 2023[52]. - The company is actively expanding into international markets, including the EU and Japan, through various marketing strategies[49]. - The company has established long-term stable partnerships with well-known clients such as Nestlé and Abbott[41]. - The company is focusing on high-value-added amino acids, such as phenylalanine and proline, to meet the growing market demand[52]. Environmental and Social Responsibility - The company adheres to national environmental regulations, with effective control of wastewater, waste gas, and noise emissions[105]. - The company has established an emergency response plan for environmental incidents and conducts regular drills[109]. - The company emphasizes clean production and environmental protection while providing high-quality products and services[107]. - The company actively participates in social responsibility initiatives, including timely payment of labor remuneration and improving employee welfare[108]. - The company is committed to complying with national and local environmental regulations, ensuring effective treatment of pollutants generated during production[187]. Corporate Governance and Shareholder Matters - The company has established new corporate governance systems during the reporting period[191]. - The company held 11 board meetings during the reporting period, addressing significant matters including the 2023 annual audit report and financial budget for 2024[198]. - The company revised its articles of association four times during the reporting period, including changes to its business scope and registered capital[195][196]. - The company has ensured that all shareholders, especially minority shareholders, can exercise their rights effectively[193]. - The company has adhered to legal procedures for major decisions, including personnel changes and investments[194]. - The company plans to distribute a cash dividend of ¥3 per 10 shares and a capital increase of 2 shares for every 10 shares held[135]. - The employee stock ownership plan involves 23 participants, with a total of 6 million shares held, representing 9.26% of the total share capital[126]. Future Outlook and Strategy - The company aims to become a global leader in the high-end amino acid industry, focusing on technological innovation and enhancing product quality[113]. - The company plans to continue its investment in new projects and equipment, as indicated by the significant changes in construction in progress and fixed assets[59]. - The company is exploring potential mergers and acquisitions as part of its growth strategy, aiming to enhance market presence[200]. - The company plans to adjust the investment amounts for fundraising projects, reflecting a proactive approach to financial management[200]. - The company will increase investment in product R&D to meet the growing demand in downstream sectors such as healthcare, biopharmaceuticals, and high-end cosmetics[115].

Financial Performance - The company's basic earnings per share decreased to 0.5500 yuan in 2024 from 0.9500 yuan in 2023, representing a decline of 42.11% [1] - The net profit for 2024 was 0.43 billion yuan, down 18.87% from 0.53 billion yuan in 2023 [1] - The return on equity fell significantly to 6.73% in 2024 from 15.47% in 2023, a decrease of 56.5% [1] - Total revenue for 2024 was 3.39 billion yuan, a decrease of 12.85% compared to 3.89 billion yuan in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 16.1298 million shares, accounting for 45.3% of the circulating shares, with an increase of 10.3874 million shares compared to the previous period [1] - Notable new shareholders include Li Songnian, holding 11.6280 million shares (32.66% of total shares), and Li Jianliang with 0.3852 million shares (1.08% of total shares) [2] - Several shareholders exited the top ten list, including Shanghai Rongsheng Private Fund Management Co., which had previously held 0.9000 million shares [2] Dividend Distribution - The company announced a dividend distribution plan of 10 yuan per share, including tax [2]

一、关联交易概述 根据公司业务发展及生产经营情况，公司对 2025 年度可能发生的日常性关联交 易进行预计，具体情况如下： | 关联交易类别 | 主要交易内容 | 预计2025年发 生金额 | 年与关联 2024 方实际发生金 | | 预计金额与上年 实际发生金额差 | | --- | --- | --- | --- | --- | --- | | | | | | | 异较大的原因 | | | | | 额 | | （如有） | | 购买原材料、燃料 | | | | | | | 和动力、接受劳务 | | | | | | | 销售产品、商品、 | 出售产品、提供 | 5,000,000.00 | | - | | | 提供劳务 | 加工 | | | | | | 委托关联方销售产 | | | | | | | 品、商品 | | | | | | | 接受关联方委托代 | | | | | | | 为销售其产品、商 | | | | | | | 品 | | | | | | 单位：元 | 其他 | | | | | | --- | --- | --- | --- | --- | | | 合计 | - | 5,000,000.00 ...